From Guidelines to Implementation: A Case Study on Applying ICH M10 for Bioanalytical Assay Cross-Validation.

Area of Science:

• Bioanalytical chemistry
• Pharmaceutical sciences
• Biomarker assay development

Background:

• Bioanalytical cross-validation is essential for data integrity across assay life cycles.
• The ICH M10 guideline offers direction but allows flexibility, leading to practice variability.
• Standardized approaches are needed for robust cross-validation study design and analysis.

Purpose of the Study:

• To present a practical framework for implementing ICH M10 cross-validation.
• To emphasize rigorous experimental design and robust statistical analysis.
• To ensure reliable bioanalytical data integration for PK/PD modeling and regulatory submissions.

Main Methods:

• Developed a framework integrating Incurred Sample Reanalysis (ISR) criteria.
• Employed Bland-Altman analysis and Deming regression for statistical assessment.
• Conducted a case study cross-validating a pharmacodynamic biomarker assay across multiple laboratories.

Main Results:

• Identified significant inter-laboratory variability in post-dose biomarker measurements.
• Found assay conditions (temperature, incubation time) significantly impacted variability.
• Observed strong alignment in pre-treatment baseline samples across laboratories.

Conclusions:

• Cross-laboratory comparisons of post-dose results are unreliable due to biomarker dynamics and assay conditions.
• The proposed framework ensures robust assessment of method variability, reflecting clinical trial data.
• The framework supports reliable bioanalytical data integration for PK/PD modeling and regulatory submissions.